Republic of the Philippines

DOST - Health Technology Assessment

The HTAC retains its recommendation for DOH to finance and include Sputnik V in the Philippine National Deployment and Vaccination Plan for COVID-19 for the general population aged 18 years and above. COVID-19 Vaccines under Emergency Use Authorization (EUA) The Food and Drug Administration (FDA) issues Emergency Use Authorization (EUA) for vaccines and drugs during public health emergencies which allows a continue reading : HTAC Recommendation: COVID-19 Vaccine Sputnik V

The HTAC recommends the DOH financing and inclusion of Covovax in the Philippine National Deployment and Vaccination Plan for COVID-19 (NDVP) for the general population aged 18 years and above. COVID-19 Vaccines under Emergency Use Authorization (EUA) The Food and Drug Administration (FDA) issues Emergency Use Authorization (EUA) for vaccines and drugs during public health emergencies which allows a shorter period continue reading : HTAC Recommendation: COVID-19 Vaccine Covovax

The HTAC recommends the DOH financing and inclusion of Sinopharm in the Philippine National Deployment and Vaccination Plan for COVID-19 Vaccines for the general population aged 18 years and above. COVID-19 Vaccines under Emergency Use Authorization (EUA) The Food and Drug Administration (FDA) issues Emergency Use Authorization (EUA) for vaccines and drugs during public health emergencies which allows a shorter period continue reading : HTAC Recommendation: COVID-19 Vaccine Sinopharm

The HTAC recommends the DOH financing and inclusion of Covaxin in the Philippine National Deployment and Vaccination Plan for COVID-19 (NDVP) for the general population aged 18 years and above. COVID-19 Vaccines under Emergency Use Authorization (EUA) The Food and Drug Administration (FDA) issues Emergency Use Authorization (EUA) for vaccines and drugs during public health emergencies which allows a shorter period continue reading : HTAC Recommendation: COVID-19 Vaccine Covaxin